POLYCYTHEMIA VERA

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This phase 2 trial tests an experimental daily pill called IMG-7289 in 4 adults with essential thrombocythemia or polycythemia vera who did not improve on standard therapy. The drug targets the LSD1 protein to help control high blood cell counts. Researchers are checking whether …

This study looks at how well the drug ropeginterferon alfa-2b works and is tolerated by people with polycythemia vera, a rare blood disorder that raises the risk of blood clots and can turn into more serious disease. About 319 adults who need this treatment will be followed for u…

This study tests a new drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The drug works by blocking a protein that controls iron use, which may lower red blood cell production and reduce the need for regular blood r…

This program offers ruxolitinib (Jakavi) to people aged 12 and older with polycythemia vera, a blood cancer that causes too many red blood cells. It is for patients whose disease has not responded to or who cannot take standard treatments like hydroxyurea. Participants take daily…

This study watches 242 adults with high-risk polycythemia vera (a rare blood cancer that thickens the blood) who have already had a blood clot. Researchers track health data like blood pressure, weight, and lab tests to see which factors best predict future clots. The goal is to …

This study examines whether people with certain blood cancers (myeloproliferative neoplasms) have autoantibodies that block a key immune protein called type I interferon. These autoantibodies may increase the risk of severe COVID-19. Researchers will test blood samples from 219 p…

This study is collecting information on quality of life and symptoms from 572 Italian patients with certain types of blood cancers called myeloproliferative neoplasms (MPNs). Participants fill out questionnaires about how their disease and treatments affect their daily functionin…